1800 605-5127
+61 (0)8 8352 7711
Alpha synuclein control peptide (116-131), Purified Peptide
As low as
US$77.00
Only %1 left
Catalog Number
PE-1606
- Product Name Alpha synuclein control peptide (116-131), Purified Peptide
- Product Description Alpha synuclein control peptide (116-131), Purified Peptide, suitable to Block.
- Alternative Names Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP
- Application(s) Block
- Purity Description > 90%
- Purity % > 90%
- Regulatory Status For research use only.
Product Info
- Product Description Alpha synuclein control peptide (116-131), Purified Peptide, suitable to Block.
- Application(s) Block
- Application Details Control Peptide. This peptide may be used to block the binding activity of antibodies to alpha synuclein ( see Biosensis antibodies S-024-100 and S-075-50).
- Target Alpha-synuclein
- Target Host Species Human
- Antigen Produced In Synthetic
- Purity Description > 90%
- Purity % > 90%
- Format Lyophilized
- Reconstitution Instructions This peptide is soluble in PBS and water.
- Storage Instructions After reconstitution keep at -20°C. Avoid repetitive freeze/thaw cycles.
- Batch Number Please see item label.
- Expiration Date 12 months after date of receipt (unopened vial).
- Alternative Names Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP
- Uniprot Number P37840
- Uniprot Number/Name P37840 (SYUA_HUMAN)
- Scientific Background Alpha synuclein is an abundant 140 amino acid neuronal protein, expressed primarily at presynaptic terminals in the central nervous system. Alpha synuclein has been associated with several neurodegenerative diseases. A point mutation in the gene coding for the alpha-synuclein protein was the first discovery linking this protein to a rare familial form of Parkinson's disease (PD). Subsequently, other mutations in the alpha-synuclein gene have been identified in familial PD. The aggregated proteinaceous inclusions called Lewy bodies found in PD and cortical Lewy body dementia (LBD) were discovered to be predominantly alpha-synuclein. Aberrant aggregation of alpha-synuclein has been detected in an increasing number of neurodegenerative diseases, collectively known as synucleopathies. Alpha-synuclein exists physiologically in both soluble and membrane-bound states, in unstructured and alpha-helical conformations, respectively. The physiological function of alpha-synuclein appears to require its translocation between these subcellular compartments and interconversion between the 2 conformations. Abnormal processing of alpha-synuclein is predicted to lead to pathological changes in its binding properties and function.
- Shipping Temperature 25°C (ambient)
- UNSPSC CODE 41105330
- Regulatory Status For research use only.